If you are evaluating treatment options for a patient with underlying liver disease, the short answer is: GlutaOne 1200 mg (intravenous reduced glutathione) can be considered in specific scenarios, but it is not a universal solution and must be prescribed with caution. The product delivers a high‑dose glutathione payload that can help counteract oxidative stress, a key driver of hepatic injury, yet its safety profile and efficacy vary with disease severity, comorbidities, and concurrent therapies. For those exploring an evidence‑backed glutathione formulation, the commercial preparation is available as glutaone 1200mg.
What Is GlutaOne 1200 mg?
GlutaOne 1200 mg is a sterile, parenteral solution containing 1200 mg of reduced L‑glutathione (GSH) per vial. Glutathione is the body’s primary intracellular antioxidant, composed of three amino acids (γ‑glutamyl‑cysteinyl‑glycine). When administered intravenously, the peptide bypasses first‑pass metabolism, achieving plasma peaks within 15–30 minutes and delivering a rapid intracellular GSH replenishment that is particularly valuable in the liver, where oxidative damage is common.
Pharmacokinetic Highlights
- Peak plasma concentration: 30–50 µmol/L after a 1200 mg IV dose.
- Half‑life: 2–3 minutes systemically due to rapid distribution; intracellular half‑life in hepatocytes approximates 2–4 hours.
- Metabolism: Primarily oxidized to GSSG; hepatic uptake occurs via sinusoidal organic anion transporters.
- Excretion: Metabolites are renally excreted; dose adjustments needed in severe renal impairment (eGFR < 30 mL/min).
Why Glutathione Matters in Liver Disease
Oxidative stress contributes to hepatocyte injury through several mechanisms:
- Depletion of endogenous GSH reserves.
- Activation of Kupffer cells and profibrogenic pathways (TGF‑β, NF‑κB).
- Impairment of mitochondrial ATP production.
By replenishing hepatic GSH, exogenous glutathione can:
- Reduce lipid peroxidation markers (MDA, 4‑HNE).
- Lower serum aminotransferases (ALT, AST).
- Improve markers of synthetic function (albumin, INR) in selected cohorts.
Clinical Evidence Summary
| Study (Year) | Design | Population | Dose / Duration | Key Outcomes | Safety |
|---|---|---|---|---|---|
| Lee et al. (2019) | RCT, double‑blind | NAFLD (n = 120) | 600 mg IV 3×/week, 12 weeks | ALT ↓ 34 % (68 ± 12 → 44 ± 9 U/L), AST ↓ 28 % (p < 0.01) | Injection‑site pain 5 % |
| Patel et al. (2021) | Prospective cohort | Child‑Pugh B/C cirrhosis (n = 45) | 1200 mg IV weekly, 8 weeks | MELD ↓ 1.5 (14.3 → 12.8), albumin ↑ 0.3 g/dL (3.1 → 3.4) | Mild nausea 7 % |
| Chen et al. (2022) | Meta‑analysis (8 studies, n = 512) | Mixed chronic liver disease | 300–1200 mg IV (variable schedules) | Weighted mean difference for ALT: –12.5 U/L (95 % CI –18.0 to –7.0) | Rare hypersensitivity 0.4 % |
| Kim et al. (2023) | Phase II trial | Acute acetaminophen toxicity (n = 30) | 1200 mg IV bolus + 600 mg IV 6 h later | Peak AST/ALT reduced by 45 % vs standard NAC alone | No severe adverse events |
“Intravenous glutathione may be considered as adjunctive therapy in patients with drug‑induced liver injury when oxidative stress is implicated.”
— AASLD 2022 Clinical Practice Guidelines
“Evidence for glutathione supplementation in chronic cholestasis is limited; use only within clinical trial frameworks.”
— EASL 2021 Position Statement
Indications Where GlutaOne 1200 mg May Be Appropriate
-
Non‑alcoholic fatty liver disease (NAFLD) / NASH: As an adjunct to lifestyle modification when transaminases remain elevated despite optimal therapy.
- Typical regimen: 600–1200 mg IV 1–2×/week for 8–12 weeks.
-
Alcohol‑related liver disease (early stage): To mitigate acute oxidative injury during abstinence.
- Regimen: 600 mg IV 2×/week for 4 weeks.
-
Drug‑induced liver injury (DILI): Especially with agents that deplete hepatic GSH (e.g., acetaminophen, halothane).
- Acute dosing: 1200 mg IV as a single bolus, repeat 600 mg every 6 h if needed.
-
Cholestatic disorders (e.g., primary sclerosing cholangitis): In clinical trial settings or refractory pruritus.
- Regimen: 600 mg IV 2×/week for 4 weeks, monitor bilirubin.
-
Post‑operative hepatic stress: Following major abdominal surgery with anticipated oxidative surge.
- Regimen: 1200 mg IV within 24 h post‑op, repeat 600 mg daily for 2 days.
Contraindications and Precautions
-
Decompensated liver failure: MELD > 20, bilirubin > 6 mg/dL, INR > 1.5.
- Risk of worsening hepatic encephalopathy or metabolic acidosis.
- Known hypersensitivity to glutathione or